Loading...
Aptus Pharma Ltd. IPO
Listed
SME
Price Range:
₹70.00
Issue Size:
₹13.02 Cr
Lot Size:
2000 shares
IPO Dates:
Sep 23, 2025 - Sep 25, 2025
Latest Subscription Data
| Category | Subscription | Status |
|---|---|---|
| QIB (Qualified Institutional Buyers) | 1.24x | Oversubscribed |
| NII (Non-Institutional Investors/HNI) | 28.75x | Oversubscribed |
| RII (Retail Individual Investors) | 31.43x | Oversubscribed |
| Total Subscription | 22.27x | Oversubscribed |
Subscription Trend Over Time
Chart Insights
Total Subscription: Shows overall IPO demand across all categories
QIB (Green): Institutional investors - typically stable demand
NII (Red): High Net Worth individuals - can be volatile
RII (Purple): Retail investors - individual participation
Dotted Lines: Sub-categories within NII based on investment size
Timeline: Shows how subscription built up during the IPO period
Share Allocation Details
Shares Offered
QIB:3,52,000
NII:2,66,000
Retail:6,20,000
Total:12,38,000
Number of Lots Offered
QIB:176
NII:133
Retail:310
Total:619
Subscription Timeline
| Date & Time | QIB | NII | Retail | Total |
|---|---|---|---|---|
| Sep 25, 2025, 05:06 PMLatest | 1.24x | 28.75x | 31.43x | 22.27x |
| Sep 24, 2025, 05:05 PM | 0.81x | 6.16x | 5.46x | 4.29x |
| Sep 23, 2025, 05:06 PM | 0.00x | 4.78x | 1.77x | 1.92x |
Understanding IPO Subscription
QIB (Qualified Institutional Buyers)
Includes mutual funds, insurance companies, FIIs, and other qualified institutions. Typically reserved 75% of the issue (excluding anchor portion).
NII (Non-Institutional Investors)
High Net Worth Individuals (HNIs) who can invest more than ₹2 lakhs. Usually allocated 15% of the issue size.
RII (Retail Individual Investors)
Individual investors who invest up to ₹2 lakhs. Reserved 10% of the issue size with better allotment chances.
Frequently Asked Questions
Get answers to the most common questions about IPO investing with Envest
No questions found matching your search.
Loading banner...
Loading banner...
Disclaimer: Subscription data is updated periodically and may not reflect real-time bidding activity. High subscription rates do not guarantee IPO allotment or listing performance. Invest wisely and consult financial advisors.